Rotavirus VP6 as a diagnostic and targeting agent

Details Rotavirus VP6 as a diagnostic and targeting agent Rotavirus VP6 as a diagnostic and targeting agent

1991-02-04

1995-07-11

Woodward, Michael P.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antigen or hapten; derivative thereof

435 5, 435 724, 4352351, 436501, 436519, 530350, 530826, A61K 5112, C12Q 170, G01N 33566, C07K 1414

Patent

active

054318998

ABSTRACT:
Advantage is taken of the ability of rotaviral VP6 protein to home to macrophage and monocytes to provide label to these cells in either an in vitro or in vivo environment. Further, the ability to couple label to the VP6 protein and to couple VP6 to a targeting agent provides a mechanism for conducting label (or an effector moiety) to any desired target.

REFERENCES:
patent: 4642232 (1987-02-01), Yman
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5102990 (1992-04-01), Rhodes
patent: 5298244 (1994-03-01), Redmond et al.
Embleton et al., "Antibody Targeting of Anti-Cancer Agents," in Monoclonal Antibodies for Cancer Detection and Therapy (Academic Press, London) Chapter 16: 317-344 (1985).
Estes et al., Nucleic Acids Res. (1984) 12:1875-1887.
Estes et al., J. Virol. (1987) 61:1488-1494.
Yeager et al., J. Cell Biol. (1990) 110:2133-2144.

Affiliated with

Also associated with

Rating

Rotavirus VP6 as a diagnostic and targeting agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rotavirus VP6 as a diagnostic and targeting agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rotavirus VP6 as a diagnostic and targeting agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-501747